![Debra J. Poul](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Loopbaan van Debra J. Poul
Eerdere bekende functies van Debra J. Poul
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Neose Technologies, Inc.
![]() Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Algemeen Adviseur | 01-01-2000 | 08-07-2010 |
Bedrijfssecretaris | 01-01-2000 | 08-07-2010 |
Opleiding van Debra J. Poul
University of Pennsylvania | Undergraduate Degree |
Villanova University | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Operationeel
General Counsel | 1 |
Corporate Secretary | 1 |
Undergraduate Degree | 1 |
Sectoraal
Consumer Services | 3 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Neose Technologies, Inc.
![]() Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
- Beurs
- Insiders
- Debra J. Poul
- Ervaring